127 related articles for article (PubMed ID: 35598839)
1. COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia.
Sookaromdee P; Wiwanitkit V
Transplant Cell Ther; 2022 Aug; 28(8):515. PubMed ID: 35598839
[No Abstract] [Full Text] [Related]
2. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya S; Luetkens T; Lutfi F; Avila S; Iraguha T; Margiotta P; Hankey KG; Lesho P; Law JY; Lee ST; Baddley J; Kocoglu M; Yared JA; Hardy NM; Rapoport AP; Atanackovic D
Blood Adv; 2022 Jan; 6(2):686-689. PubMed ID: 34941995
[No Abstract] [Full Text] [Related]
3. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
4. Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients.
Oh BLZ; Tan N; de Alwis R; Kunasegaran K; Chen Z; Poon M; Chan E; Low JGH; Yeoh AEJ; Bertoletti A; Le Bert N
Blood; 2022 Jul; 140(2):156-160. PubMed ID: 35472242
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Kochenderfer JN; Dudley ME; Feldman SA; Wilson WH; Spaner DE; Maric I; Stetler-Stevenson M; Phan GQ; Hughes MS; Sherry RM; Yang JC; Kammula US; Devillier L; Carpenter R; Nathan DA; Morgan RA; Laurencot C; Rosenberg SA
Blood; 2012 Mar; 119(12):2709-20. PubMed ID: 22160384
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
10. B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
Chen GM; Melenhorst JJ; Tan K
Sci Transl Med; 2022 Jun; 14(650):eabn3353. PubMed ID: 35731887
[TBL] [Abstract][Full Text] [Related]
11. CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma.
Buchtele N; Wohlfarth P; Staudinger T; Schellongowski P; Traby L; Vossen M; Knaus H; Lobmeyr E; Rabitsch W; Worel N; Staber PB
Ann Hematol; 2023 Jan; 102(1):231-234. PubMed ID: 36399193
[No Abstract] [Full Text] [Related]
12. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
[TBL] [Abstract][Full Text] [Related]
13. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
Davila ML; Kloss CC; Gunset G; Sadelain M
PLoS One; 2013; 8(4):e61338. PubMed ID: 23585892
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
[TBL] [Abstract][Full Text] [Related]
15. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy.
Hill JA; Giralt S; Torgerson TR; Lazarus HM
Blood Rev; 2019 Nov; 38():100596. PubMed ID: 31416717
[TBL] [Abstract][Full Text] [Related]
16. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
18. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
19. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
[TBL] [Abstract][Full Text] [Related]
20. CART attack.
Pillai V; Maude SL
Blood; 2017 Jul; 130(2):229. PubMed ID: 28705860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
